晚期透明细胞肾细胞癌患者一线酪氨酸激酶抑制剂临时暂停治疗对比持续治疗的STAR试验:开放标签、非劣效性、随机对照2/3期试验
STAR试验在英国60家医院纳入920例晚期透明细胞肾细胞癌患者,随机分为常规持续治疗组(n=461)与无药间期策略组(n=459),比较总生存与质量调整生命年(QALY)的非劣效性。结果显示总生存非劣效性仅在意向性治疗(ITT)人群中成立(校正HR 0.97,95%CI 0.83-1.12),QALY在ITT和符合方案人群中均达到非劣效。总体非劣效性未能确立,但组间预期寿命未见有临床意义的缩短,治疗间歇可能为可行且具成本效益的选择。
要点
- 总生存非劣效性仅在ITT人群成立(校正HR 0.97,95%CI 0.83-1.12),符合方案人群未达非劣效(HR 0.94,95%CI 0.80-1.09)。
- QALY在ITT(边际效应差0.06,95%CI -0.11至0.23)和符合方案人群(0.04,95%CI -0.14至0.21)均达非劣效。
- 最常见≥3级不良事件为高血压(持续组26% vs 无药间期组29%)、肝毒性(11% vs 11%)和乏力(8% vs 15%)。
核心结论
- 总体非劣效性未能确立,但无药间期策略与常规持续策略组间预期寿命似无临床意义缩短,治疗间歇可能是可行且具成本效益的选择,并带来生活方式获益。
研究设计与样本
- 开放标签、非劣效性、随机对照2/3期试验,在英国60家医院开展。
- 纳入920例患者,随机1:1分配至常规持续治疗组(n=461)或无药间期策略组(n=459)。
- 所有患者先接受标准剂量口服舒尼替尼(50 mg/日)或口服帕唑帕尼(800 mg/日)治疗24周,之后进入随机分组。
- 无药间期策略组暂停治疗直至疾病进展后再重新开始治疗。
- 共同主要终点为总生存和质量调整生命年(QALY),在意向性治疗(ITT)人群和符合方案人群中评估。
主要发现
- 中位随访时间:ITT人群58个月(IQR 46-73个月),符合方案人群58个月(46-72个月)。
- 总生存:ITT人群校正HR 0.97(95%CI 0.83至1.12);符合方案人群HR 0.94(95%CI 0.80至1.09)。
- QALY边际效应差:ITT人群(n=919)0.06(95%CI -0.11至0.23);符合方案人群(n=871)0.04(95%CI -0.14至0.21)。
- 最常见≥3级不良事件:高血压持续组124/485例(26%)vs无药间期组127/431例(29%);肝毒性55例(11%)vs 48例(11%);乏力39例(8%)vs 63例(15%)。
- 920例参与者中192例(21%)发生严重不良反应;报告12例治疗相关死亡(持续组3例,无药间期组9例)。
关键数值与推荐
- 总生存非劣效界值:双侧95%CI下限HR≥0.812。
- QALY非劣效界值:平均QALY边际差异的双侧95%CI下限≥-0.156。
- 仅当两个终点在ITT和符合方案两个分析人群中均达到非劣效时,才可判定总体非劣效。
临床怎么用
- 原文结论认为总体非劣效性未能确立,但无药间期策略与常规持续策略组间预期寿命似无临床意义缩短,治疗间歇可能是可行且具成本效益的选择,并带来生活方式获益。
局限性
- 原文结论指出总体非劣效性未能确立。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Temporary drug treatment cessation might alleviate toxicity without substantially compromising efficacy in patients with cancer. We aimed to determine if a tyrosine kinase inhibitor drug-free interval strategy was non-inferior to a conventional continuation strategy for first-line treatment of advanced clear cell renal cell carcinoma. METHODS: This open-label, non-inferiority, randomised, controlled, phase 2/3 trial was done at 60 hospital sites in the UK. Eligible patients (aged ≥18 years) had histologically confirmed clear cell renal cell carcinoma, inoperable loco-regional or metastatic disease, no previous systemic therapy for advanced disease, uni-dimensionally assessed Response Evaluation Criteria in Solid Tumours-defined measurable disease, and an Eastern Cooperative Oncology Group performance status of 0-1. Patients were randomly assigned (1:1) at baseline to a conventional continuation strategy or drug-free interval strategy using a central computer-generated minimisation programme incorporating a random element. Stratification factors were Memorial Sloan Kettering Cancer Center prognostic group risk factor, sex, trial site, age, disease status, tyrosine kinase inhibitor, and previous nephrectomy. All patients received standard dosing schedules of oral sunitinib (50 mg per day) or oral pazopanib (800 mg per day) for 24 weeks before moving into their randomly allocated group. Patients allocated to the drug-free interval strategy group then had a treatment break until disease progression, when treatment was re-instated. Patients in the conventional continuation strategy group continued treatment. Patients, treating clinicians, and the study team were aware of treatment allocation. The co-primary endpoints were overall survival and quality-adjusted life-years (QALYs); non-inferiority was shown if the lower limit of the two-sided 95% CI for the overall survival hazard ratio (HR) was 0·812 or higher and if the lower limit of the two-sided 95% CI of the marginal difference in mean QALYs was -0·156 or higher. The co-primary endpoints were assessed in the intention-to-treat (ITT) population, which included all randomly assigned patients, and the per-protocol population, which excluded patients in the ITT population with major protocol violations and who did not begin their randomisation allocation as per the protocol. Non-inferiority was to be concluded if it was met for both endpoints in both analysis populations. Safety was assessed in all participants who received a tyrosine kinase inhibitor. The trial was registered with ISRCTN, 06473203, and EudraCT, 2011-001098-16. FINDINGS: Between Jan 13, 2012, and Sept 12, 2017, 2197 patients were screened for eligibility, of whom 920 were randomly assigned to the conventional continuation strategy (n=461) or the drug-free interval strategy (n=459; 668 [73%] male and 251 [27%] female; 885 [96%] White and 23 [3%] non-White). The median follow-up time was 58 months (IQR 46-73 months) in the ITT population and 58 months (46-72) in the per-protocol population. 488 patients continued on the trial after week 24. For overall survival, non-inferiority was demonstrated in the ITT population only (adjusted HR 0·97 [95% CI 0·83 to 1·12] in the ITT population; 0·94 [0·80 to 1·09] in the per-protocol population). Non-inferiority was demonstrated for QALYs in the ITT population (n=919) and per-protocol (n=871) population (marginal effect difference 0·06 [95% CI -0·11 to 0·23] for the ITT population; 0·04 [-0·14 to 0·21] for the per-protocol population). The most common grade 3 or worse adverse events were hypertension (124 [26%] of 485 patients in the conventional continuation strategy group vs 127 [29%] of 431 patients in the drug-free interval strategy group); hepatotoxicity (55 [11%] vs 48 [11%]); and fatigue (39 [8%] vs 63 [15%]). 192 (21%) of 920 participants had a serious adverse reaction. 12 treatment-related deaths were reported (three patients in the conventional continuation strategy group; nine patients in the drug-free interval strategy group) due to vascular (n=3), cardiac (n=3), hepatobiliary (n=3), gastrointestinal (n=1), or nervous system (n=1) disorders, and from infections and infestations (n=1). INTERPRETATION: Overall, non-inferiority between groups could not be concluded. However, there seemed to be no clinically meaningful reduction in life expectancy between the drug-free interval strategy and conventional continuation strategy groups and treatment breaks might be a feasible and cost-effective option with lifestyle benefits for patients during tyrosine kinase inhibitor therapy in patients with renal cell carcinoma. FUNDING: UK National Institute for Health and Care Research.
引用
- Brown JE, Royle KL, Gregory W, et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial. Lancet Oncol. 2023. PMID: 36796394. doi:10.1016/S1470-2045(22)00793-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。